Welcome to our dedicated page for MindWalk Holdings news (Ticker: HYFT), a resource for investors and traders seeking the latest updates and insights on MindWalk Holdings stock.
MindWalk Holdings Corp. reports developments in Bio-Native AI drug discovery, biologics research, and AI-driven therapeutic development. Company updates center on its patented HYFT technology and LensAI platform, which combine biological sequence, structure, function, literature analysis, and wet-lab validation for biologics discovery workflows.
Recurring news themes include financial results, enterprise platform contracts, North American biologics services activity, and product or program updates. Announcements have covered B Cell Llama for VHH nanobody discovery, B Cell Select, universal influenza research, functional-adjacency analysis for AI-designed therapeutics, and antibody or intrabody discovery work involving pathogenic TDP-43 in neurodegenerative disease.
MindWalk (HYFT) reported a production deployment of the open-source OpenFold3 structure prediction model using AMD Inference Microservices on Vultr Kubernetes Engine, powered by AMD Instinct MI325X GPUs.
The company ran end-to-end production workloads across proteins, RNA, DNA, ligands and antibody-antigen complexes inside its ReefIQ-governed discovery workflows. A production-grade prediction environment was deployed in minutes, and antibody-antigen inference time was approximately 5x faster than in MindWalk’s prior environment. The deployment validates MindWalk’s model-agnostic architecture, expands compute capacity beneath ReefIQ as enterprise partners onboard, and independently validates AMD Inference Microservices for OpenFold3 in a life sciences production setting.
MindWalk (HYFT) reported fiscal Q1 2027 revenue of $3.8 million, up 21% year over year, with gross margin expanding to 58.6% from 48.3%.
Gross profit rose 47% to $2.2 million as cost of sales held near $1.6 million. Operating expenses increased 47% to $8.4 million, driving an operating loss of $6.1 million and net loss from continuing operations of $6.1 million, or $0.13 per share, compared with $4.1 million, or $0.09 per share, a year earlier. Adjusted EBITDA loss widened to $5.1 million from $3.7 million. Net cash used in operating activities improved slightly to $4.0 million, while cash declined to $7.6 million from $11.3 million at April 30, 2026.
The quarter included the commercial launch of ReefIQ™, and about 80% of the commercial funnel by value is now in partnership-structured engagements. After quarter-end, MindWalk secured a binding commitment for a senior unsecured revolving credit facility of up to US$30 million at a fixed 7.00% rate, with no financial maintenance covenants, no warrants or conversion feature, and no pledge of assets, to support its shift to recurring, platform-based revenue.
MindWalk Holdings (HYFT) secured a binding commitment for a senior unsecured revolving credit facility of up to US$30 million from Sanabil (Cayman) to fund biologics programs and commercial expansion.
The facility carries a fixed annual interest rate of 7.00% on drawn amounts only, an initial term of 36 months, and a possible 12‑month extension by agreement. It includes no financial maintenance covenants, no warrants, no equity conversion features, no asset pledge, and no material adverse change condition to closing. MindWalk is not obligated to borrow, may prepay without penalty, and will pay a one‑time 1.00% opening fee with no unused line fee. A definitive credit agreement consistent with the binding term sheet is targeted to close within 60 days.
MindWalk Holdings (HYFT) will participate in the H.C. Wainwright 28th Annual Global Investment Conference, held September 14–16, 2026, at the Lotte New York Palace Hotel in New York.
A pre-recorded fireside chat featuring CEO Dr. Jennifer Bath and H.C. Wainwright biotechnology research managing director Dr. Swayampakula Ramakanth will be available on demand to registered attendees starting September 11, 2026, at 7:00 a.m. ET via the conference platform. Dr. Bath will also hold one-on-one investor meetings during the event.
MindWalk Holdings Corp. (HYFT) will report financial results for the first quarter of fiscal year 2027 and host an earnings conference call on Monday, September 14, 2026, at 5:00 p.m. Eastern Time.
The financial results will be released in a press release prior to the call. The event will include a management presentation followed by a question-and-answer session. The live webcast and replay will be available via a link in the Events section of MindWalk’s Investor Relations website.
Analysts can register through a dedicated analyst URL, while other attendees have a separate webcast access link. Listeners are encouraged to review MindWalk’s periodic reports on SEDAR+ and the SEC website for risk factors and historical financial information.
MindWalk Holdings (NASDAQ: HYFT) presented the first public demonstration of its ReefIQ™ biological context layer for AI drug discovery running on AMD Instinct™ at AMD’s Advancing AI 2026 event in San Francisco. The demo, part of the AMD Instinct Demo Showcase, was accompanied by an AMD-distributed video interview.
ReefIQ, introduced in June 2026, sits between client discovery data and AI workflows, reconnecting fragmented biological data into governed, queryable context that AI models and agents can reason over. Built on MindWalk’s HYFT® biological pattern technology and exposed to LensAI™, it aims to preserve program knowledge, support regulated governance, and run on open, memory-rich AMD Instinct infrastructure.
MindWalk Holdings (NASDAQ: HYFT) reported fiscal 2026 revenue of $15.6 million, up 46% from $10.6 million, with gross profit rising to $9.1 million and gross margin expanding to 58.8% from 53.9%. Net loss from continuing operations narrowed to $15.1 million from $33.1 million, while loss per share from continuing operations improved to $0.33 from $0.99.
According to MindWalk, total operating expenses declined 44% to $24.1 million, mainly due to the non-recurrence of about $22.7 million of prior-year non-cash amortization and impairment charges. The company divested its Netherlands subsidiary, generating approximately $14.3 million in proceeds, completed its rebranding to MindWalk Holdings to reflect its Bio-Native AI focus, regained Nasdaq compliance, and authorized a discretionary buyback of up to 2.3 million shares (~5% of shares then outstanding). It also signed its first two recurring LensAI platform contracts and, after year-end, launched its ReefIQ context layer and was added to the Russell 3000E and Russell Microcap indexes.
MindWalk Holdings (NASDAQ: HYFT), a Bio-Native AI company, will report financial results for its fourth quarter and full fiscal year 2026 on Wednesday, July 22, 2026, at 5:00 p.m. Eastern Time. The company will host an earnings conference call with a management presentation and Q&A.
The financial results will be released in a press release before the call. The live webcast and replay will be accessible via the Events section of MindWalk’s investor relations site. Participants can also join by phone using the provided U.S. and Canadian toll and toll-free dial-in numbers.
MindWalk Holdings (NASDAQ: HYFT) has been added to the Russell 3000E Index, effective after the U.S. market close on June 26, 2026, following FTSE Russell’s June 2026 semi-annual reconstitution.
The index covers up to 4,000 large U.S. companies, with about $12.2 trillion benchmarked to Russell US Indexes, expanding HYFT’s visibility and eligibility among institutional and index-tracking investors.
MindWalk (NASDAQ: HYFT) filed European patent application EP26187897.9 for a high-dimensional biological data architecture underpinning its HYFT® Technology, ReefIQ™ context layer, and LensAI™ reasoning workflows.
The model-agnostic layer is designed to organize reusable biological meaning for AI-enabled drug discovery across customer programs and platforms.